In a report released yesterday, Stephen Macleod from BMO Capital maintained a Buy rating on Jamieson Wellness Inc (JWEL – Research Report), with a price target of C$41.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Stephen Macleod’s rating is based on Jamieson Wellness Inc.’s strong performance and promising outlook. The company’s Q4/24 results and 2025 guidance were in line with expectations, demonstrating solid revenue growth and robust consumption trends, particularly in key markets like China and the U.S. The 2025 guidance indicates a return to low double-digit adjusted EBITDA growth, suggesting the company is well-positioned to achieve its long-term revenue target of over $1 billion.
Additionally, Jamieson Wellness Inc. benefits from favorable secular trends and has shown resilience in its operating results, with a notable increase in adjusted EBITDA and margin improvements. The company’s strategic investments, especially in China, are expected to drive further growth, while the risk-reward profile of the stock remains attractive. These factors collectively support Stephen Macleod’s Buy rating for the stock.
According to TipRanks, Macleod is a 5-star analyst with an average return of 11.5% and a 58.20% success rate. Macleod covers the Consumer Cyclical sector, focusing on stocks such as Aritzia, Gildan Activewear, and CCL Industries.
In another report released today, RBC Capital also maintained a Buy rating on the stock with a C$40.00 price target.